Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension

Tetsuya Oshima1, Ryoji Ozono, Yoko Yano

  • 1Department of Clinical Laboratory Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. teto@hiroshima-u.ac.jp

Insights

T-type calcium channel blockers, unlike L-type blockers, significantly improved endothelial function in essential hypertension patients. Efonidipine reduced oxidative stress markers, suggesting a novel therapeutic approach for hypertension-related vascular dysfunction.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Pharmacology

Background:

  • Essential hypertension is characterized by impaired endothelial function.
  • Voltage-gated T-type Ca2+ channels, but not L-type, are present in the vascular endothelium.

Purpose of the Study:

  • To investigate the role of T-type Ca2+ channels in endothelial dysfunction in essential hypertension.
  • To compare the effects of a T- and L-type Ca2+ channel blocker (efonidipine) versus an L-type Ca2+ channel blocker (nifedipine) on endothelial function.

Main Methods:

  • Flow-mediated vasodilation (FMD) and nitroglycerin (NTG)-induced vasodilation were assessed in 40 hypertensive patients and 20 controls.
  • Patients received either efonidipine or nifedipine for 12 weeks.
  • Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and serum malondialdehyde-modified LDL were measured.

Main Results:

  • Hypertensive patients showed attenuated FMD compared to controls.
  • Both efonidipine and nifedipine similarly reduced mean blood pressure.
  • Efonidipine significantly improved the endothelial function index (FMD/NTG) and reduced oxidative stress markers (8-OHdG, modified LDL), while nifedipine did not.

Conclusions:

  • T-type Ca2+ channel blockade, exemplified by efonidipine, may improve endothelial dysfunction in essential hypertension.
  • The improvement in endothelial function by efonidipine appears linked to a reduction in oxidative stress.
  • L-type Ca2+ channel blockade alone may not be sufficient to restore endothelial function in this patient group.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...